Disclosed herein is a process for preparing a highly concentrated allergenic intermediate from a dilute allergen extract. This process involves providing a crude extract comprising biological material from an allergenic source, where the biological material comprises a solid phase portion and a liquid phase portion; concentrating the crude extract using pervaporation; adjusting the pH of the concentrated crude extract to 4.0-5.0; treating the concentrated extract with a ketonic solvent to form a precipitate; and recovering the precipitate by filtration to obtain a highly concentrated allergenic intermediate.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
(1) Medical diagnostic apparatus; medical diagnostic test for allergies; skin-testing device for allergies; device for application of allergenic extract skin tests.
Medical diagnostic apparatus for testing allergic reactions on skin; skin-testing device for allergies, namely, medical devices for skin-testing allergic reaction; medical device for application of allergenic extract skin tests.
4.
PREPARATION OF HIGHLY CONCENTRATED ALLERGENIC INTERMEDIATE
Disclosed herein is a process for preparing a highly concentrated allergenic intermediate from a dilute allergen extract. This process involves providing a crude extract comprising biological material from an allergenic source, where the biological material comprises a solid phase portion and a liquid phase portion; concentrating the crude extract using pervaporation; adjusting the pH of the concentrated crude extract to 4.0 – 5.0; treating the concentrated extract with a ketonic solvent to form a precipitate; and recovering the precipitate by filtration to obtain a highly concentrated allergenic intermediate.
Disclosed herein are methods for the preparation of allergenic extracts. In one embodiment, the methods are carried out without having to adjust the pH of the extraction phase. The methods provide efficient recovery of allergenic extract from allergenic source material.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely, allergenic extracts for treating symptoms of allergies and allergenic extracts for allergy skin tests Medical diagnostic apparatus, namely, percutaneous testing device; medical diagnostic test for allergies in the nature of percutaneous testing device; skin-testing device for allergies, namely, percutaneous prick or scratch device for application to the skin for determining allergic reactions; device for application of allergenic extract skin tests, namely, percutaneous prick or scratch device for application to the skin for determining allergic reactions Medical consulting services in the field of allergy diagnosis and treatment
The present invention relates to synergistic antimicrobial compositions comprising quaternary ammonium compound and antimicrobial active, process of preparing the same and their use. The compositions of the present invention possess activity at lower concentration of the actives and are environmentally benign.
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
Disclosed herein is cost effective and eco-friendly process for producing quaternary pyridinium salts and their hydrates thereof, with high yield and purity at industrial scale.
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
The present invention relates to an industrially feasible and economically viable process for the preparation of 2-fluoro-6-(trifluoromethyl)pyridine compounds of Formula (I). The process comprises fluorination of one or more pyridine compounds of Formula (II) with a fluorinating agent and isolating 2-fluoro-6-(trifluoromethylpyridine compound of Formula (I) obtained, which are useful as intermediates in the synthesis of many agrochemical and pharmaceutical products.
The present invention provides an improved process for the preparation of exametazime, which is used as ligand in preparation of technetium-99m complex. Formula (I)
The present invention discloses a stable biocidal composition with enhanced antifungal activity at low concentration of active (s) and a process for preparing the same. The composition comprises: zinc pyrithione, C8-C18 quaternary ammonium salt (preferably cetylpyridinium chloride), water miscible glycol/polyol/glycol ether/lactam, organic amine and/or alkanol amine. The composition can be formulated into: hair care formulations, antidandruff hair care formulations, water based paints, coatings, adhesives, hard surface cleaners, fabric care compositions, wood products, plastic products and medical products. The biocidal compositions and the resulting formulations are transparent or opaque and are stable at varying pH and humidity conditions.
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
A01N 33/08 - AminesQuaternary ammonium compounds containing oxygen or sulfur
A01N 25/02 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
A01N 25/30 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
The present invention provides an improved and commercial process for the preparation of Lacosamide having formula (I). Further, the present invention also provides the novel intermediate compounds of formula (VI) and (VII) and their process for the preparation. Present process utilizes compound of formula (VI) and (VI)I as key novel intermediates for the preparation of Lacosamide.
C07C 271/22 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
C07C 231/14 - Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
The invention relates to a substantially pure linezolid hydroxide having R-isomer content more than about 99.9% relative to its S-isomer. Further aspect of invention provides the ambient moisture condition, which is critical for enantiomeric pure linezolid hydroxide. The obtained substantially enantiomerically pure linezolid hydroxide compound of formula-II can be subsequently converted into the linezolid compound of formula-I, having S-isomer content more than 99.9% relative to R-isomer. Further the invention provides an improved process for preparation of enantiomeric pure linezolid Form-I, wherein linezolid Form-I having the purity more than 99.9% relative to any other known polymorphic form of linezolid. The obtained enantiomeric pure linezolid Form-I can be subsequently converted into the other known polymorphic forms linezolid. The invention also provides stable and substantially solvent-free crystal of Form-I of linezolid.
The present invention provides a commercially viable, cost effective and energy efficient process for the preparation of 2-pyridinylmethylsulfinyl benzimidazoles, their analogs and optically active enantiomers or pharmaceutically acceptable salts, hydrates or solvates thereof in high purity via application of reactors such as plug flow reactor, microreactor, microfluidic flow reactor, tubular flow reactor, coil-type flow reactor, laminar flow reactor, packed bed reactor, fluidized bed reactor or fixed bed reactor.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
16.
SOLID STATE FORMS OF AZILSARTAN AND AZILSARTAN MEDOXOMIL MONOPOTASSIUM AND PREPARATION THEREOF
The present invention relates to novel solid state forms of azilsartan and azilsartan medoxomil monopotassium salt i.e. amorphous and crystalline forms of azilsartan and azilsartan medoxomil monopotassium salt and processes for the preparation thereof. The present invention also relates to co-precipitate of azilsartan. Further, it relates to the pharmaceutical composition of amorphous and crystalline forms of azilsartan and azilsartan medoxomil monopotassium salt and its use.
C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
The present invention provides a novel process and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially renin inhibitors, such as Aliskiren, or a salt thereof, preferably Aliskiren hemifumarate.
C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
C07D 307/33 - Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
18.
IMPROVED CATALYTIC PROCESS FOR PRODUCTION OF PYRIDINE CARBOXYLIC ACID AMIDES
An improved catalytic process for the production of pyridine carboxylic acid amides, by catalytic hydration reaction of pyridine nitriles with solid heterogeneous catalyst wherein the process involve effective utilization and recycling of the catalytic components, and reactants.
Disclosed herein is an improved process for the preparation of anpiprazole in anhydrous Type I crystals, substantially free of other polymorphic forms of aripiprazole via improved drying technique.
C07D 215/227 - Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
20.
PROCESS FOR THE PREPARATION OF (S)-(+)-OR (R)-(-)-10 HYDROXY DIHYDRODIBENZ[B,F]AZEPINES BY ENANTIOSELECTIVE REDUCTION OF 10, 11-DIHYDRO-10-OXO-5H-DIBENZ[B,F]AZEPINES AND POLYMORPHS THEREOF
The present invention provides a novel process for the preparation of substituted optically pure (S)-(+)- or (R)-(-)-10-hydroxy-dihydrodibenz[b, f]azepines or derivatives thereof, starting from 10,11-dihydro-10-oxo-5H-dibenz[b,f]azepines using boronate esters or their derivatives. The- present invention also provides use of thus prepared (S)-(+)- or (R)-(-)-10-hydroxy-dihydrodibenz[b,f]azepines for the preparation of their ester such as (S)-(-)-10-acetoxy-10,11-dihydro-5H-dibenz[b, f]azepine-5-carboxamide or (R)-(+)-10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide. The present invention also provides novel solid state crystalline forms J1, J2, J3, J4 and amorphous form of eslicarbazepine and the process for the preparation thereof. Also, the present invention provides novel solid state crystalline form and amorphous form of eslicarbazepine acetate and the process for the preparation thereof. The novel solid state forms of eslicarbazepine are useful for the preparation of derivatives of eslicarbazepine such as eslicarbazepine acetate.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61P 25/00 - Drugs for disorders of the nervous system
21.
AN IMPROVED PROCESS FOR THE PREPARATION OF AZILSARTAN MEDOXOMIL
The present invention relates to an improved process for the preparation of azilsartan or its esters or salts thereof. Specifically, the invention provides a method for the preparation of highly pure methyl 1-[[2'-(4,5-dihydro-5-oxo-4H-1,2,4-oxadiazol-3- yl)biphenyl-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7 -carboxylate an intermediate compound of formula (4) for azilsartan medoxomil with reduced content of desethyl impurity. The invention also involves the use of highly pure methyl 1-[[2'-(4,5-dihydro- 5-oxo-4H-1,2,4-oxadiazol-3-yl) biphenyl-4-yl] methyl]-2-ethoxy-1H-benzirnidazole-7- carboxylate in the preparation of azilsartan or its esters or salts thereof, preferably medoxomil with reduced content of desethyl impurity.
C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
22.
AN IMPROVED PROCESS FOR THE PREPARATION OF ANTIHISTAMINIC DRUGS VIA A NOVEL CARBAMATE INTERMEDIATE
The present invention relates to a novel racemic or optically active carbamate intermediate of formula (IV A). This novel racemic or optically active carbamate intermediate of formula (IV A) can be used to prepare drugs having antihistaminic activity such as cetirizine (IA), meclizine (IB), chlorcyclizine (IC), clocinizine (ID), buclizine (IE) and enantiomers thereof such as levocetirizine (I). Further, disclosed herein is an improved process for the preparation of levocetirizine via a novel optically active intermediate i.e. compound of formula (IV). Also, disclosed herein is a novel process for the preparation of compound (II) and for crystallization of its salt.
C07D 295/088 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
C07D 295/205 - Radicals derived from carbonic acid
Disclosed herein is an improved process for producing aminopyridine compounds analogs, substituted forms, derivatives, or the pharmaceutically acceptable salts, esters, amides and prodrugs thereof with high purity and yield at industrial scale.
The present invention provides novel solid state forms of azilsartan medoxomil and process for the preparation thereof. The solid state forms of the present invention includes crystalline forms viz. J2, J3, J4, J5, J6, J7, J8, J9 and amorphous forms of azilsartan medoxomil. Further, it relates to the pharmaceutical composition and use of the said formulation to treat the conditions in a subject in need thereof.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
The present invention, relates to novel amine salts of rosuvastatin and its process for the preparation. Moreover, the present invention also relates to improved process for the preparation of rosuvastatin calcium, employing novel amine salts as an intermediate.
Disclosed herein is an improved process for the preparation of pure N-Pentanoyl-N-[[2'- (1h-Tetrazol-5-Yl)[1,1'-Biphenyl]-4-Yl]Methyl]-L-Valine employing highly active carbon.
PROCESS FOR PRODUCING ENANTIOMERICALLY ENRICHED ISOMER OF 3-(1-AMINOETHYL) PHENYL DERIVATIVE AND EMPLOYING THE SAME TO PRODUCE RIVASTIGMINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT
The present invention relates to an economic and efficient process for producing enatiomerically enriched 3-(1-aminoethyl)phenyl derivative and employing the same to produce Rivastigmine or its pharmaceutically acceptable salt.
C07C 303/08 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof by substitution of hydrogen atoms by sulfo or halosulfonyl groups by reaction with halogenosulfonic acids
C07C 303/42 - SeparationPurificationStabilisationUse of additives
C07C 309/73 - Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
Disclosed herein a compressed tablet composition comprising (a) coated multiple units, containing at least one active pharmaceutical ingredient, (b) at least one compressibility enhancing agent comprising neutral spheres, (c) at least one cohesiveness imparting agent comprising binder(s). Such a composition provides solution to chipping, cracking and leaking problems associated with compression of coated multiple units (pellets or beads).
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
The present invention provides improved processes for the preparation of linezolid, going through a novel intermediate of formula XIa, which avoids the use of sodium azide and formation of bis-linezolid as an impurity. It also provides the process for preparation of linezolid, free of bis-linezolid through benzylamine intermediate (XIII). Also, it provides the process of preparation of linezolid by preparing azide intermediate, which further converts into linezolid in one-pot. Linezolid with high yield and high chemical purity is obtained without the use of tedious, complicated purification steps, such as chromatography or repeated recrystallization.
C07D 211/32 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
31.
PROCESS FOR THE PREPARATION OF DULOXETINE HYDROCHLORIDE AND ITS PRECURSORS
The present invention relates to an improved process for racemizing one of the enantiomers, or an enantiomerically enriched mixture, of an optically active compound (S)-N, N-dimethyl-3-(2-thienyl)-3-hydroxypropanamine, a key intermediate used for the preparation of (S)-N-methyl-3-(1-naphthalenyloxy)-3-(2- thienyl) propanamine (duloxetine) or its hydrochloride salt. Moreover, the present invention also relates to an improved process for the preparation of (S)-N-methyl-3- (1-naphthalenyloxy)-3-(2-thienyl) propanamine (duloxetine) or its hydrochloride salt having low content of undesired R-isomer and chiral purity not less than 99%.
Disclosed herein is an improved process for the preparation of 7-(4-bromobutoxy) 3,4-dihydrocarbostyril, a key intermediate used in the preparation of Aripiprazole.
Disclosed herein is a process for producing optically active 1-n-propyl-2',6'-dimethyl-2-piperidinecarboxanilide. The process comprises of reacting n-propyl pipecolate ester with 2,6-dimethylanilino magnesium halide. The 1-n-propyl-2',6'-dimethyl-2-piperidinecarboxanilide obtained according to the process is having chiral purity of more than 97%.
Disclosed herein is a stabilized pharmaceutical composition of benzimidazole compounds preferably amorphous form of esomeprazole and a process for preparing the same. Furthermore, the invention discloses the pharmaceutical compositions formulated into solid dosage forms preferably multiple unit tablet dosage forms and capsules and a method for preparing the same.
A61K 9/54 - Sustained or differential release type containing discrete particles with coatings of different thicknesses or different materials
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
35.
STABLE PHARMACEUTICAL COMPOSITIONS OF MONTELUKAST OR ITS SALTS OR SOLVATES OR HYDRATES
Disclosed herein is a stable pharmaceutical composition comprising a therapeutically effective amount of montelukast or its pharmaceutically acceptable salts, solvates or hydrates and a blend comprising microcrystalline cellulose and a flavoring agent and wherein said composition is substantially free of montelukast sulfoxide degradation product. Also the process for preparing such composition is provided.
A01N 43/42 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
Disclosed herein are novel intermediates and process for large scale production of (S)- 3-[(1-dimethylamino) ethyl] phenyl-N-ethyl-N-methyl-carbamate (rivastigmine) or its pharmaceutically acceptable salts employing the novel intermediates. Further provided are methods for producing the novel intermediates thereof.
C07C 213/00 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
C07C 269/00 - Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups
C07C 309/73 - Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
C07C 215/50 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
C07C 271/44 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
39 - Transport, packaging, storage and travel services
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Contract manufacturing of prescription pharmaceutical and healthcare products for others, namely, packaging and repackaging of prescription pharmaceutical and healthcare products to the order and specification of others; storage of prescription pharmaceutical and healthcare products and packaging and repackaging of prescription pharmaceutical and healthcare products for transportation. Manufacture of prescription pharmaceutical and healthcare products to the order and/or specification of others. Development of and providing quality assurance services in the field of prescription pharmaceutical and healthcare products.
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Data management services. Providing on-line, web-based information and seminars regarding clinical research tools. Web-based platform featuring hosted software for use in electronic data capture for deployment of studies and for use in managing work flow, documents and data used in and generated by an auditable evaluation and reporting process for evaluating existing research, namely, systematic reviews and clinical research.
42 - Scientific, technological and industrial services, research and design
Goods & Services
on-line web based platform featuring hosted software for managing work flow, documents, and data used in relation to evaluating research results in all disciplines, namely, systematic reviews of research work
Medical diagnostic apparatus; medical diagnostic test for allergies; skin-testing device for allergies; device for application of allergenic extract skin tests
39 - Transport, packaging, storage and travel services
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Contract manufacturing of prescription pharmaceutical and non-prescription pharmaceutical products for others, namely, packaging and repackaging of prescription pharmaceutical and non-prescription pharmaceutical products to the order and specification of others and the distribution of prescription pharmaceutical and non-prescription pharmaceutical products for others; storage of prescription pharmaceutical and non-prescription pharmaceutical products and packaging and repackaging of prescription pharmaceutical and non-prescription pharmaceutical products for transportation; manufacture of prescription pharmaceutical and non-prescription pharmaceutical products to the order and/or specification of others; and development of and providing quality assurance services in the field of prescription pharmaceutical and non-prescription pharmaceutical products.
